PUR Stock Overview
A biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pure Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł17.80 |
| 52 Week High | zł33.20 |
| 52 Week Low | zł5.01 |
| Beta | 1.41 |
| 11 Month Change | 2.18% |
| 3 Month Change | -15.24% |
| 1 Year Change | 71.81% |
| 33 Year Change | -78.02% |
| 5 Year Change | -46.39% |
| Change since IPO | -22.27% |
Recent News & Updates
Recent updates
Here's Why We're Watching Pure Biologics Spólka Akcyjna's (WSE:PUR) Cash Burn Situation
Dec 06
We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Aug 14Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?
Apr 30We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Jan 03We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To Grow
Apr 21Shareholder Returns
| PUR | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -7.0% | -4.1% | -3.1% |
| 1Y | 71.8% | -16.8% | -1.7% |
Return vs Industry: PUR exceeded the Polish Biotechs industry which returned -16.8% over the past year.
Return vs Market: PUR exceeded the Polish Market which returned -1.7% over the past year.
Price Volatility
| PUR volatility | |
|---|---|
| PUR Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: PUR's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: PUR's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 4 | n/a | purebiologics.com |
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
Pure Biologics S.A. Fundamentals Summary
| PUR fundamental statistics | |
|---|---|
| Market cap | zł67.21m |
| Earnings (TTM) | -zł34.35m |
| Revenue (TTM) | zł312.00k |
210.7x
P/S Ratio-1.9x
P/E RatioIs PUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PUR income statement (TTM) | |
|---|---|
| Revenue | zł312.00k |
| Cost of Revenue | zł2.05m |
| Gross Profit | -zł1.73m |
| Other Expenses | zł32.62m |
| Earnings | -zł34.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.30 |
| Gross Margin | -555.77% |
| Net Profit Margin | -11,009.29% |
| Debt/Equity Ratio | -273.6% |
How did PUR perform over the long term?
See historical performance and comparison